Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720798 | 0.85 | CYP2D6 (0.58) | CYP2D6KCNH2PPARGPPARADHFR | |
| SCHEMBL3199098 | 0.85 | CYP2D6 (0.53) | CYP2D6KCNH2PPARGPPARA | |
| SCHEMBL9692722 | 0.84 | DHFR (0.48) | CYP2D6KCNH2DHFRTSHR | |
| SCHEMBL14382693 | 0.84 | CYP2D6 (0.57) | CYP2D6KCNH2PPARGPPARADHFR | |
| SCHEMBL9428212 | 0.81 | THRA (0.43) | MEN1KMT2ATSHR | |
| SCHEMBL17509790 | 0.81 | PPARA (0.68) | CYP2D6KCNH2PPARGPPARATSHR | |
| SCHEMBL9492166 | 0.81 | PPARA (0.68) | CYP2D6KCNH2PPARGPPARATSHR | |
| SCHEMBL21974573 | 0.81 | MEN1 (0.63) | MEN1KMT2APPARGPPARA | |
| SCHEMBL16502341 | 0.80 | ALDH1A1 (0.54) | MEN1KMT2ATSHR | |
| SCHEMBL9621361 | 0.80 | CYP2D6 (0.53) | CYP2D6KCNH2PPARGPPARADHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | disclosed |
| CN-101687773-A | Substituted 2- [ 2- (phenyl) ethylamino ] alkanamide derivatives and their use as sodium and/or calcium channel modulators | NEWRON PHARM SPA | 2010-03-31 | — | — | CN | disclosed |
| EP-2155663-A1 | SUBSTITUTED 2- Ý2- (PHENYL) ETHYLAMINO¨ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | Newron Pharmaceuticals S.p.A. (IT) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008151702-A1 | SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | MEN1 3711/4885KMT2A 698/4885CYP2D6 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.